Sacituzumab govitecan receives fast approval from the FDA for advanced urothelial cancer

Share This Post

August 2021: Sacituzumab govitecan (Trodelvy, Immunomedics Inc.) was given accelerated approval by the Food and Drug Administration for patients with locally advanced or metastatic urothelial cancer (mUC) who had previously received platinum-based chemotherapy and either a programmed death receptor-1 (PD-1) or a programmed death ligand 1 (PD-L1) inhibitor.

TROPHY (IMMU-132-06; NCT03547973) was a single-arm, multicenter trial that enrolled 112 patients with locally advanced or metastatic UC who had previously received platinum-based chemotherapy and either a PD-1 or PD-L1 inhibitor. On days 1 and 8 of a 21-day therapy cycle, patients received 10 mg/kg sacituzumab govitecan intravenously.

The major efficacy outcomes were the objective response rate (ORR) and duration of response (DOR), which were assessed using RECIST 1.1 criteria by an independent review. With 5.4 percent complete responses and 22.3 percent partial responses, the confirmed ORR was 27.7% (95 percent CI: 19.6, 36.9). The median DOR (n=31; 95 percent CI: 4.7, 8.6; range 1.4+, 13.7) was 7.2 months.

Neutropenia, nausea, diarrhoea, lethargy, alopecia, anaemia, vomiting, constipation, decreased appetite, rash, and stomach discomfort are the most prevalent side events (incidence >25%) in patients taking sacituzumab govitecan.

Until disease progression or intolerable toxicity, the recommended sacituzumab govitecan dose is 10 mg/kg once weekly on days 1 and 8 of 21-day therapy cycles.


Reference :

Check details here.

Take second opinion on urethral cancer treatment

Spread the love

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Development of CAR T Cell therapy in Korea
Cancer treatment in South Korea

Companies in Korea takes a step closer in developing home grown CAR T-Cell therapy

Due to high costs, treatments developed by multinational pharmaceutical corporations are difficult for Korean patients to access. As a result, Korean businesses have created and localised CAR-T treatments in an effort to address these issues. Many businesses have either begun developing CAR-T therapies or declared their intention to do so, including Curocell, Abclon, GC Cell, Ticaros, Helixmith, Toolgen, Cllengene, Eutilex, and Vaxcell Bio.

Spread the love
Blood cancer

Polatuzumab vedotin-piiq is approved by USFDA for previously untreated diffuse large B-cell lymphoma, not otherwise specified, and high-grade B-cell lymphoma

For adult patients with high-grade B-cell lymphoma (HGBL), not otherwise specified (NOS), or diffuse large B-cell lymphoma (DLBCL) who have not previously received treatment and who have an International Prognostic Index (IPI) score of 2 or higher, the Food and Drug Administration has approved polatuzumab vedotin-piiq (Polivy, Genentech, Inc.).

Spread the love

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

درمان سرطان در تركيه

Enquiry Form